STEFANINI, Giulio Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 4259
EU - Europa 774
AF - Africa 179
AS - Asia 69
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 5298
Nazione #
US - Stati Uniti d'America 4244
FI - Finlandia 208
NG - Nigeria 177
SE - Svezia 102
FR - Francia 93
DE - Germania 86
NL - Olanda 73
IE - Irlanda 67
IT - Italia 52
GB - Regno Unito 29
BE - Belgio 27
TR - Turchia 25
CA - Canada 14
IL - Israele 8
RU - Federazione Russa 8
GR - Grecia 7
SG - Singapore 7
A2 - ???statistics.table.value.countryCode.A2??? 5
HK - Hong Kong 5
RO - Romania 5
ES - Italia 4
IN - India 4
BR - Brasile 3
CL - Cile 3
JP - Giappone 3
AT - Austria 2
AU - Australia 2
IR - Iran 2
MD - Moldavia 2
PH - Filippine 2
SA - Arabia Saudita 2
TH - Thailandia 2
TW - Taiwan 2
UA - Ucraina 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
CN - Cina 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
ID - Indonesia 1
IM - Isola di Man 1
KW - Kuwait 1
KZ - Kazakistan 1
ME - Montenegro 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
VN - Vietnam 1
Totale 5298
Città #
Chandler 988
Wilmington 959
San Mateo 418
Ann Arbor 231
Helsinki 208
Lawrence 182
Princeton 182
Benin City 177
Leawood 148
Woodbridge 99
Fairfield 91
Paris 89
Amsterdam 72
Boardman 72
Dublin 67
Brussels 27
Kocaeli 24
London 24
Seattle 22
Milan 21
Norwalk 20
San Diego 20
Falkenstein 14
Hanover 13
Redmond 13
Toronto 13
Abbiategrasso 10
Redwood City 10
Des Moines 8
Cambridge 5
Clearwater 4
Houston 4
Los Angeles 4
Augsburg 3
Badia Polesine 3
Gunzenhausen 3
Kemerovo 3
Monmouth Junction 3
Stockholm 3
São Paulo 3
Athens 2
Central 2
Chisinau 2
Cupertino 2
Delhi 2
Duncan 2
Phoenix 2
Taipei 2
Vittoria 2
Almaty 1
Arvada 1
Auckland 1
Baltimore 1
Bangkok 1
Belgrade 1
Bilgi 1
Caloocan City 1
Central District 1
Chennai 1
Chicago 1
Douglas 1
Dundee 1
Durban 1
Ferrara 1
Frankfurt am Main 1
Granada 1
Groningen 1
Hanoi 1
Henderson 1
Hunedoara 1
Izhevsk 1
Jacksonville 1
Jakarta 1
Kashan 1
Kiel 1
Kowloon 1
Kuala Lumpur 1
Kuwait City 1
Laguna Niguel 1
Las Vegas 1
Lima 1
Lisbon 1
Ljubljana 1
Manila 1
Mountain View 1
New York 1
Pitesti 1
Podgorica 1
Queens 1
Quito 1
Québec 1
Riyadh 1
Rome 1
Saint Paul 1
Sam Phran 1
San José 1
Singapore 1
Solihull 1
Sydney 1
Tuen Mun 1
Totale 4329
Nome #
CAD in TAVI patients: relevance of disease complexity 56
Does clinical data quality affect fluid-structure interaction simulations of patient-specific stenotic aortic valve models? 55
On the Modeling of Patient-Specific Transcatheter Aortic Valve Replacement: A Fluid-Structure Interaction Approach 51
2014 ESC/EACTS Guidelines on myocardial revascularization 50
How should I treat a DES restenosis in a graft anastomosis with challenging access and multiple previous coronary interventions? 48
The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study 48
Impact of Diabetes on Clinical Outcomes After Polymer-Free Amphilimus- and Biolimus-Eluting Stent Implantation 47
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. 47
Coral Reef Aorta: A Rare Occlusive Disease of the Aorta Complicating Decision Making for Severe Aortic Stenosis Treatment. 47
Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention. 46
What constitutes sufficient clinical evidence for stents? SpotLITE on the evaluation of novel coronary devices. 46
2014 ESC/EACTS Guidelines on myocardial revascularization. 45
Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Milan, Italy 45
Endovascular treatment vs. intravenous thrombolysis alone for ischaemic stroke: a meta-analysis of randomised controlled trials 44
Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: an updated systematic review and meta-analysis 44
Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom (TM) drug-coated stent vs. the Gazelle (TM) bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy 44
2018 ESC/EACTS Guidelines on myocardial revascularization. 44
Efficacy and Safety of Calcium Channel Blocker/Diuretics Combination Therapy in Hypertensive Patients: A Meta-Analysis. 43
Coronary stents: novel developments 43
Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients. 43
Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. 43
2014 ESC/EACTS Guidelines on myocardial revascularization 43
New approach to direct stenting using a novel 'All-In-One' coronary stent system via 5 french diagnostic catheters: A pilot study 43
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 43
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 43
State of the art: coronary artery stents - past, present and future. 42
What's new in the 2018 ESC/EACTS guidelines on myocardial revascularization? 41
Management of ST-elevation myocardial infarction according to European and American guidelines. 41
Is Transcatheter Aortic Valve Replacement Superior to Surgical Aortic Valve Replacement? A Meta-Analysis of Randomized Controlled Trials. 41
2018 ESC/EACTS Guidelines on myocardial revascularization. 41
Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. 41
Myocardial revascularization appropriateness in Italy: measuring the unmeasured. 40
Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. 40
Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. 40
Aspiration Thrombectomy for Treatment of ST-segment Elevation Myocardial Infarction: a Meta-analysis of 26 Randomized Trials in 11 943 Patients 39
Surgical or percutaneous revascularization for isolated left anterior descending stenoses: are we in the same boat? 38
Can Coronary Computed Tomography Angiography Replace Invasive Angiography? Coronary Computed Tomography Angiography Cannot Replace Invasive Angiography 38
Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. 38
The Contemporary Pulse of Bioresorbable-Scaffold Thrombosis Among Expert Operators 37
The synergy stent in high-bleeding risk patients: why design matters 37
4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New Generation Drug-Eluting Stents in the RESOLUTE All Comers Randomized Trial. 37
Predictors of Adverse Events Among Patient Undergoing Primary Percutaneous Coronary Intervention - Insights From a Pooled Analysis of the COMFORTABLE-AMI and EXAMINATION trials 37
Evolving Routine Standards in Invasive Hemodynamic Assessment of Coronary Stenosis: The Nationwide Italian SICI-GISE Cross-Sectional ERIS Study. 37
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. 36
Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. 36
Are the culprit lesions severely stenotic? 36
2018 ESC/EACTS Guidelines on myocardial revascularization 36
Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry. 36
Another reason to endorse and spread guidelines 36
ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes 36
Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 36
Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents A Meta-Analysis 35
Transcatheter aortic valve implantation using the ACURATE neo in bicuspid and tricuspid aortic valve stenosis: a propensity-matched analysis of a European experience. 35
Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. 35
Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement. 35
Severe aortic stenosis and coronary artery disease. 35
Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When? Interv Cardiol. 34
Two-year clinical follow-up of the unrestricted use of the paclitaxel-eluting stent compared to the sirolimus-eluting stent as part of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry 34
Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in Small Aortic Annuli: The TAVI-SMALL Registry. 34
Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. 34
Offline fusion of co-registered intravascular ultrasound and frequency domain optical coherence tomography images for the analysis of human atherosclerotic plaques. 34
Drug-Eluting Coronary Artery Stents 33
Higher in-hospital mortality during weekend admission for acute coronary syndrome: a large-scale cross-sectional Italian study 33
Role of Niacin in current clinical practice: A systematic review 33
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial 33
An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use? 33
Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. 33
Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents A Patient-Level Pooled Analysis of Randomized Controlled Trials 33
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. 33
Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review 33
The Valsalva maneuver in the diagnosis of patent foramen ovale. 32
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. 32
Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. 32
A new device for vascular embolization: report on case of two pulmonary arteriovenous fistulas embolization using the amplatzer vascular plug 32
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. 32
Safety and efficacy of polymer-free biolimus-eluting stents in all-comer patients: the RUDI-FREE study. 32
Quantitative angiographic characterization of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. 32
Safety and Efficacy of Polymer-Free Drug-Eluting Stents 32
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents. 31
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials 31
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 31
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial 31
New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. 31
Preoperative scallop-by-scallop assessment of mitral prolapse using 2D-transthoracic echocardiography. 31
Structure and functioning of the Heart Team: primum non nocere 31
Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. 31
Coronary artery disease in patients undergoing TAVI: why, what, when and how to treat. 31
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 31
Independent impact of extent of coronary artery disease and percutaneous revascularization on 30-day and 1-year mortality after TAVI: a meta-analysis of adjusted observational results. 31
Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19 31
Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality 30
New-Generation Drug-Eluting Stents for Left Main In-Stent Restenosis: The DELTA-2 Registry. 30
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration 30
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. 30
Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients 30
Early Doppler-echocardiography evaluation of 597 prosthetic aortic valves. 29
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention Results of a Nonrandomized Observational Study 29
Stent performance: never too late to sort it out. 29
Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents 29
Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation 29
Totale 3709
Categoria #
all - tutte 32183
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32183

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0000 00 00 0004
2020/20211822 41234 13498 340135 3832422186
2021/2022905 241016246 62 21149 736824644
2022/20232848 423110237316 317209 29218 5232901760
Totale 5579